On Tuesday March 10th SMSbiotech, Inc submitted their proposal to the Biomedical Advanced Research and Development Authority (BARDA) to conduct a pilot clinical study on mechanically ventilated patients with Covid-19 associated pneumonitis.
SMSbiotech was founded in 2015 and is established in southern California.
SMSbiotech has developed for many years a patented technology to isolate human Small Mobile Stem (SMS) cells. SMS cells have many unique features including small size, mobility and proliferation potential.
SMS cells interact strongly with various other adult cells such as vascular endothelial cells, fibroblasts and mesenchymal stem cells (of different tissue origin). In vitro data suggest these interactions could be beneficial to human in vivo organ repair and regeneration.
Small Mobile Stem (SMS) cell has been shown in animal experiments to promote, repair and regenerate damaged tissue and organs. Currently SMS cells are used to produce large amounts of angiogenic extracellular matrices for research (commercial assays) and for forthcoming therapeutic purposes. The application of SMS cells of allogeneic source, grown and manufactured under GMP conditions, is proposed as a potential effective treatment that could repair critically damaged tissues by the coronavirus. The advantage of that medical approach is largely independent of the specific viral strain and its ability to mutate.
The Proposed Action Plan includes conducting the pilot clinical study on mechanically ventilated patients with Covid-19 associated pneumonitis using SMS cells.